Lumleian > Lumleian Difference > Universal and Novel Data

Universal and Novel Data

Lumleian delivers more than traditional primary research and secondary data typical in life science consulting. We codify and validate next generation data applying proprietary techniques that result in measurable time and cost savings for our clients.

We don’t waste time gathering the basics. We deliver relevant information on day one.

Lumleian's strategy for capturing real-time data presented with keen insight provides incomparable support for modern R&D decision makers engaged in:

  • Early Stage In-Licensing: By disease state, data from the scientific literature, NIH grants, and patent databases can be mined to identify and prioritize leading targets, mechanisms, investigators, and research institutions.
     
  • Late Stage Portfolio Optimization: Across disease states, data from the clinical literature can be mined to benchmark competitor trial designs, levels of clinical investment, and to improve estimates for the likelihood of technical, regulatory, and clinical success.